Lilly Completes Acquisition of CoLucid Pharmaceuticals
INDIANAPOLIS, IN, March 1, 2017 – Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of CoLucid Pharmaceuticals, Inc. (NASD:CLCD). The tender offer for all outstanding shares of common stock of CoLucid, at a price of $46.50 per share, expired as scheduled on Tuesday, February 28, 2017.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.